Continuous Reduced Nonrelapse Mortality after Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Institution's Three Decade Experience

Biology of Blood and Marrow Transplantation

Volumn 20, Issue 8, 2014, Pages 1217-1223

  Malard, Florent ^a,b   Chevallier, Patrice ^a   Guillaume, Thierry ^a   Delaunay, Jacques ^a   Rialland, Fanny ^c   Harousseau, Jean Luc ^a,d,e   Moreau, Philippe ^a,d   Mechinaud, Francoise ^c,f   Milpied, Noel ^a,g   Mohty, Mohamad ^a,h,i,j  

^a UNIVERSITÉ DE NANTES   (France)

^b Groupe Cytokines et Récepteurs   (France)

^c NANTES UNIVERSITY HOSPITAL   (France)

^d Centre D'Investigation Clinique en Cancérologie CI2C   (France)

^e CENTRE RENÉ GAUDUCHEAU   (France)

^f ROYAL CHILDREN'S HOSPITAL   (Australia)

^g BORDEAUX UNIVERSITY HOSPITAL   (France)

^h HÔPITAL SAINT ANTOINE   (France)

ⁱ SORBONNE UNIVERSITÉ   (France)

^j INSERM   (France)

more..

Author keywords

Allogeneic stem cell transplantation; Nonrelapse mortality; Overall survival

Indexed keywords

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; APLASTIC ANEMIA; ARTICLE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DONOR; FEMALE; HUMAN; HUMAN CELL; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; MYELOABLATIVE CONDITIONING; TREATMENT OUTCOME; ADOLESCENT; ADVERSE EFFECTS; AGED; ALLOTRANSPLANTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOSUPPRESSIVE TREATMENT; RETROSPECTIVE STUDY; SURVIVAL; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 84904055208     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2014.04.021     Document Type: Article

References (43)

1. Thomas E., Storb R., Clift R.A., et al. Bone-marrow transplantation (first of two parts). N Engl J Med 1975, 292:832-843.
2. Bensinger W.I., Buckner C.D., Shannon-Dorcy K., et al. Transplantation of allogeneic CD34+ peripheral blood stem cells in patients with advanced hematologic malignancy. Blood 1996, 88:4132-4138.
3. Schmitz N., Dreger P., Suttorp M., et al. Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor). Blood 1995, 85:1666-1672.
4. Gluckman E., Broxmeyer H.A., Auerbach A.D., et al. Hematopoietic reconstitution in a patient with Fanconi's anemia by means of umbilical-cord blood from an HLA-identical sibling. N Engl J Med 1989, 321:1174-1178.
5. Slavin S., Nagler A., Naparstek E., et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998, 91:756-763.
6. Giralt S., Estey E., Albitar M., et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997, 89:4531-4536.
7. Sorror M.L., Giralt S., Sandmaier B.M., et al. Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences. Blood 2007, 110:4606-4613.
8. Storb R., Deeg H.J., Whitehead J., et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 1986, 314:729-735.
9. Brissot E., Chevallier P., Guillaume T., et al. Prophylaxis with mycophenolate mofetil and CsA can decrease the incidence of severe acute GVHD after antithymocyte globulin-based reduced-intensity preparative regimen and allo-SCT from HLA-matched unrelated donors. Bone Marrow Transplant 2010, 45:786-788.
10. Malard F., Szydlo R.M., Brissot E., et al. Impact of cyclosporine-A concentration on the incidence of severe acute graft-versus-host disease after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2010, 16:28-34.
11. Saral R., Burns W.H., Laskin O.L., et al. Acyclovir prophylaxis of herpes-simplex-virus infections. N Engl J Med 1981, 305:63-67.
12. Eisen D., Essell J., Broun E.R., et al. Clinical utility of oral valacyclovir compared with oral acyclovir for the prevention of herpes simplex virus mucositis following autologous bone marrow transplantation or stem cell rescue therapy. Bone Marrow Transplant 2003, 31:51-55.
13. Roy V., Ochs L., Weisdorf D. Late infections following allogeneic bone marrow transplantation: suggested strategies for prophylaxis. Leuk Lymphoma 1997, 26:1-15.
14. Schmidt G.M., Horak D.A., Niland J.C., et al. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants; The City of Hope-Stanford-Syntex CMV Study Group. N Engl J Med 1991, 324:1005-1011.
15. Goodrich J.M., Mori M., Gleaves C.A., et al. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. N Engl J Med 1991, 325:1601-1607.
16. Wagner H.J., Cheng Y.C., Huls M.H., et al. Prompt versus preemptive intervention for EBV lymphoproliferative disease. Blood 2004, 103:3979-3981.
17. Peric Z., Cahu X., Chevallier P., et al. Features of Epstein-Barr Virus (EBV) reactivation after reduced intensity conditioning allogeneic hematopoietic stem cell transplantation. Leukemia 2011, 25:932-938.
18. Goodman J.L., Winston D.J., Greenfield R.A., et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992, 326:845-851.
19. Attal M., Huguet F., Rubie H., et al. Prevention of hepatic veno-occlusive disease after bone marrow transplantation by continuous infusion of low-dose heparin: a prospective, randomized trial. Blood 1992, 79:2834-2840.
20. Glucksberg H., Storb R., Fefer A., et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974, 18:295-304.
21. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995, 15:825-828.
22. Shulman H.M., Sullivan K.M., Weiden P.L., et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980, 69:204-217.
23. Filipovich A.H., Weisdorf D., Pavletic S., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005, 11:945-956.
24. Horwitz M.E. Reduced intensity versus myeloablative allogeneic stem cell transplantation for the treatment of acute myeloid leukemia, myelodysplastic syndrome and acute lymphoid leukemia. Curr Opin Oncol 2011, 23:197-202.
25. Anasetti C., Hansen J.A. Effect of HLA incompatibility in marrow transplantation from unrelated and HLA-mismatched related donors. Transfus Sci 1994, 15:221-230.
26. Flomenberg N., Baxter-Lowe L.A., Confer D., et al. Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome. Blood 2004, 104:1923-1930.
27. Yakoub-Agha I., Mesnil F., Kuentz M., et al. Allogeneic marrow stem-cell transplantation from human leukocyte antigen-identical siblings versus human leukocyte antigen-allelic-matched unrelated donors (10/10) in patients with standard-risk hematologic malignancy: a prospective study from the French Society of Bone Marrow Transplantation and Cell Therapy. J Clin Oncol 2006, 24:5695-5702.
28. Mielcarek M., Storer B.E., Sandmaier B.M., et al. Comparable outcomes after nonmyeloablative hematopoietic cell transplantation with unrelated and related donors. Biol Blood Marrow Transplant 2007, 13:1499-1507.
29. Cahu X., Rialland F., Touzeau C., et al. Infectious complications after unrelated umbilical cord blood transplantation in adult patients with hematologic malignancies. Biol Blood Marrow Transplant 2009, 15:1531-1537.
30. Malard F., Furst S., Loirat M., et al. Effect of graft source on mismatched unrelated donor hemopoietic stem cell transplantation after reduced intensity conditioning. Leukemia 2013, 27:2113-2117.
31. Luznik L., O'Donnell P.V., Fuchs E.J. Post-transplantation cyclophosphamide for tolerance induction in HLA-haploidentical bone marrow transplantation. Semin Oncol 2012, 39:683-693.
32. Blaise D., Kuentz M., Fortanier C., et al. Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: a report from the Societe Francaise de Greffe de Moelle. J Clin Oncol 2000, 18:537-546.
33. Flowers M.E., Inamoto Y., Carpenter P.A., et al. Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. Blood 2011, 117:3214-3219.
34. Bacigalupo A., Lamparelli T., Barisione G., et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biol Blood Marrow Transplant 2006, 12:560-565.
35. Mohty M., Labopin M., Balere M.L., et al. Antithymocyte globulins and chronic graft-vs-host disease after myeloablative allogeneic stem cell transplantation from HLA-matched unrelated donors: a report from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. Leukemia 2010, 24:1867-1874.
36. Finke J., Bethge W.A., Schmoor C., et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol 2009, 10:855-864.
37. Ferrara J.L., Levine J.E., Reddy P., Holler E. Graft-versus-host disease. Lancet 2009, 373:1550-1561.
38. Jagasia M., Arora M., Flowers M.E., et al. Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood 2012, 119:296-307.
39. Goodyear O.C., Dennis M., Jilani N.Y., et al. Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML). Blood 2012, 119:3361-3369.
40. Anguille S., Willemen Y., Lion E., et al. Dendritic cell vaccination in acute myeloid leukemia. Cytotherapy 2012, 14:647-656.
41. Bastos-Oreiro M., Perez-Corral A., Martinez-Laperche C., et al. Prognostic impact of minimal residual disease analysis by flow cytometry in patients with acute myeloid leukaemia before and after allogeneic haemopoietic stem cell transplantation. Eur J Haematol 2014.
42. Corradini P., Carniti C. Molecular methods for detection of minimal residual disease following transplantation in lymphoid and plasma cell disorders. Methods Mol Biol 2014, 1109:209-237.
43. Alatrash G., de Lima M., Hamerschlak N., et al. Myeloablative reduced-toxicity i.v. busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth decades of life. Biol Blood Marrow Transplant 2011, 17:1490-1496.